Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF‑β/TβR and Imp7/8
Open Access
- 12 June 2018
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (2) , 1052-1060
Abstract
Compound Astragalus and Salvia miltiorrhiza extract (CASE) is a Chinese herbal formula consisting of astragalosides, astragalus polysaccharide and salvianolic acids extracted from Astragalus membranaceus and Salvia miltiorhiza. Previous studies by our group have demonstrated that CASE effectively suppresses diethylinitrosamine (DEN)‑induced hepatocellular carcinoma (HCC) in rats via modulating transforming growth factor β/Mothers against decapentaplegic (TGFβ/Smad) signaling. To further elucidate the mechanism of CASE, the effects of CASE on TGF‑β1, the serine/threonine kinase receptors of TGF‑β [TGF‑β receptor type‑I (TβRΙ) and TβRII] and karyopherins [Importin 7 (Imp7) and Imp8], which are crucial for TGF‑β/Smad signaling in fibro‑hepatocarcinogenesis, were assessed in the present study using in vivo (DEN‑induced HCC in rats) and in vitro [TGF‑β1‑stimulated rat myofibroblasts (MFBs) and HepG2 cells] models of fibro‑hepatocarcinogenesis. Hematoxylin and eosin staining revealed that CASE may suppress inflammatory reactions and fibrosis in HCC as well as increasing the differentiation of HCC cells. Positive TGF‑β1 staining was increased in HCC nodule areas and in adjacent normal liver tissues in DEN‑treated rats, while TβRΙ staining was increased only in normal adjacent liver tissues. The elevated expression of TGF‑β1, TβRΙ and TβRII was suppressed by CASE. CASE treatment also reduced glutathione S‑transferase P 1 and Imp7/8 protein expression in fibro‑hepatocarcinogenesis. In vitro experiments confirmed that CASE was able to decrease the expression of TβRΙ and TβRII in TGF‑β1‑stimulated MFBs and HepG2 cells. These results indicate that the anti‑HCC effect of CASE may be achieved by mediating TGF‑β/TβR and Imp7/8 protein expression, suggesting that CASE has multiple targets in HCC treatment.Keywords
This publication has 37 references indexed in Scilit:
- Prevalence of hepatocellular carcinoma in Chinese Budd–Chiari syndrome patientsEuropean Journal of Gastroenterology & Hepatology, 2013
- Meta-Analysis of the Clinical Value of Danshen Injection and Huangqi Injection in Liver CirrhosisEvidence-Based Complementary and Alternative Medicine, 2013
- Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamstersExperimental and Therapeutic Medicine, 2011
- Mechanisms of hepatic fibrogenesisBest Practice & Research Clinical Gastroenterology, 2011
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironmentThrombosis Research, 2010
- TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β SignalingMolecular Cell, 2009
- Preferential Utilization of Imp7/8 in Nuclear Import of SmadsJournal of Biological Chemistry, 2008
- Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF‐β dependent fashionJournal of Cellular Physiology, 2006
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003